Drug intelligence / Profile preview

UTR-HER2-NSCLC-ex19del

Development stage: Preclinical
Lead developer: UTR Therapeutics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

UTR-HER2-NSCLC-ex19del is an investigational RNA-based therapeutic being developed by UTR Therapeutics. It is designed to reduce or inhibit the expression of the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) by targeting the untranslated regions (UTRs) of the mRNA. This candidate is specifically tailored for the treatment of non-small cell lung cancer (NSCLC) that is HER2-positive and carries an EGFR exon 19 deletion (ex19del) mutation. The drug is currently in the Pre-IND/IND-enabling stage of development, aiming to provide a targeted treatment option for this specific molecular subset of lung cancer by modulating protein expression at the translational level.

Other names: UTR-HER2-UTR Therapeutics-HER2/ERBB2-RNA Therapeutic-HER2+ EGFR exon 19 deletion (ex19del) NSCLC

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on UTR-HER2-NSCLC-ex19del.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UTR-HER2-NSCLC-ex19del.

Explore the full profile